The role of genetic testing in the prediction of response to EGFR inhibitors in XXXX .

@entity5 @entity1149 @entity1 @entity2
@entity2 is the leading cause of @entity5 deaths worldwide. @entity1149 ( @entity1149 ) is the largest subgroup of the disease and accounts for approximately 80% of @entity2 . Most @entity1 with @entity1149 are diagnosed with locally advanced or metastatic disease. The current treatment options for such @entity1 are associated with substantial limitations in efficacy and safety. Targeted therapies have provided some improvement in clinical outcomes. Recent efforts have focused on identifying specific markers that are predictive of response to treatment. A pretreatment detection of such markers could facilitate a more personalized and specific approach to therapy, whereby the most appropriate and efficacious treatment is selected for a specific subset of @entity1 . Such a tailored approach would maximize both the therapeutic index and cost-effectiveness of treatments. In addition, several novel agents are under development, which may have the potential for overcoming acquired resistance to existing treatments. This supplement will review the current and emerging treatments for @entity1 with advanced @entity1149 and the molecular predictors of response that may facilitate the future clinical application of personalized medicine.
